Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) Research & Development (2016 - 2025)

Historic Research & Development for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $90.0 million.

  • Viking Therapeutics' Research & Development rose 29479.04% to $90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.5 million, marking a year-over-year increase of 14406.15%. This contributed to the annual value of $101.6 million for FY2024, which is 5930.16% up from last year.
  • As of Q3 2025, Viking Therapeutics' Research & Development stood at $90.0 million, which was up 29479.04% from $60.2 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Research & Development ranged from a high of $90.0 million in Q3 2025 and a low of $9.8 million during Q4 2021
  • In the last 5 years, Viking Therapeutics' Research & Development had a median value of $16.2 million in 2022 and averaged $24.0 million.
  • Per our database at Business Quant, Viking Therapeutics' Research & Development crashed by 1232.18% in 2023 and then skyrocketed by 29479.04% in 2025.
  • Over the past 5 years, Viking Therapeutics' Research & Development (Quarter) stood at $9.8 million in 2021, then surged by 64.29% to $16.2 million in 2022, then rose by 26.73% to $20.5 million in 2023, then soared by 51.14% to $31.0 million in 2024, then skyrocketed by 190.29% to $90.0 million in 2025.
  • Its Research & Development was $90.0 million in Q3 2025, compared to $60.2 million in Q2 2025 and $41.4 million in Q1 2025.